← feed

Is NCT03222310 results overdue?

Yes — results are overdue. Primary completion was 2017-09-06; the FDAAA-801 reporting deadline (2018-09-06) passed 2845 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

NCT IDNCT03222310 ↗
SponsorHoffmann-La Roche (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-09-06 (ACTUAL)
Reporting deadline2018-09-06 (completion + 365d)
Days overdue2845
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 bb167a1328368e33… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03222310. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →